Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. (ORGO) – Schedule 13D/A (Amendment 10) filed 06/24/2025
The filing updates beneficial ownership information for a long-standing reporting group comprised of company founders, related trusts and affiliated investment vehicles. No purchase or sale prices are disclosed in the excerpt; however, the cover page states that the amendment was triggered by an event on June 24 2025.
Key ownership positions disclosed
- Alan A. Ades: 22,319,836 shares (17.6% of Class A common), of which 11.2 million are held with sole voting/dispositive power and 11.1 million with shared power.
- Albert Erani: 17,920,498 shares (14.1%) – approximately 6.8 million sole and 11.1 million shared.
- Glenn H. Nussdorf: 11,912,841 shares (9.4%) – 11.0 million sole, 0.9 million shared.
- Dennis Erani: 10,043,701 shares (7.9%) – 1.3 million sole, 8.7 million shared.
- Organo PFG LLC: 8,279,490 shares (6.5%) – all sole voting/dispositive.
- Other entities & individuals: Organo Investors LLC (2.9 million / 2.2%), Alan Ades 2014 GRAT (3.1 million / 2.4%) and Starr Wisdom (20,000 / <0.1%).
Based on the amounts reported, the group collectively controls approximately 76.4 million Class A shares. Although total shares outstanding are not provided in the excerpt, each of the first four individuals continues to exceed the 5% reporting threshold, indicating significant insider alignment with shareholders. The amendment does not specify whether positions increased or decreased relative to the prior filing.
No financial performance metrics, transaction prices or strategic commentary accompany the ownership data, suggesting that the filing is largely administrative—updating share counts and voting arrangements among a pre-existing insider group.
Organogenesis Holdings Inc. (Nasdaq: ORGO) filed an 8-K covering the results of its 23 June 2025 Annual Meeting and a preferred-stock director election.
Board & Executive Matters
- Series A Convertible Preferred holders unanimously re-elected Garrett Lustig to the Board.
- All nine management-nominated directors were re-elected; the highest support was 72.4 million votes (95.8% of votes cast) for Gilberto Quintero, while the lowest was 68.9 million (93.9%) for Jon Giacomin.
- Say-on-Pay advisory resolution passed with 91.4% support (67.1 m for / 6.3 m against).
Capital Structure Proposal
- Shareholders approved—by 45.4 m for vs. 2.7 m against—the potential issuance of >20% of outstanding Class A shares upon conversion of Series A Preferred below Nasdaq “minimum price,” a step that could be deemed a change-of-control under Rules 5635(b)/(d).
Audit Matters
- RSM US LLP was ratified as independent auditor for FY 2025 with 96.4% support (103.6 m for / 3.9 m against).
Quorum: 107.5 million Class A votes were present (inclusive of 25.4 m as-converted preferred shares, subject to Nasdaq’s 19.99% cap).
The filing is largely routine governance disclosure; however, the preferred-stock conversion approval introduces potential future dilution that current shareholders should monitor.